RecruitingPhase 2NCT04895436
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Studying B-cell chronic lymphocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AbbVie
- Principal Investigator
- ABBVIE INC.AbbVie
- Intervention
- Venetoclax(drug)
- Enrollment
- 75 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2029
Study locations (30)
- Moores Cancer Center at UC San Diego /ID# 230157, La Jolla, California, United States
- Winship Cancer Institute of Emory University /ID# 230643, Atlanta, Georgia, United States
- Des Moines Oncology Research Association /ID# 232606, Des Moines, Iowa, United States
- Dana-Farber Cancer Institute /ID# 230061, Boston, Massachusetts, United States
- Henry Ford Hospital /ID# 230268, Detroit, Michigan, United States
- St. Lukes Hospital of Duluth /ID# 250021, Duluth, Minnesota, United States
- Hattiesburg Clinic /ID# 233443, Hattiesburg, Mississippi, United States
- Summit Medical Group-Florham Park /ID# 244782, Florham Park, New Jersey, United States
- Regional Cancer Care Associates /ID# 244620, Hackensack, New Jersey, United States
- University of North Carolina /ID# 233313, Chapel Hill, North Carolina, United States
- Novant Health Presbyterian Medical Center /ID# 230201, Charlotte, North Carolina, United States
- Novant Health Forsyth Medical Center /ID# 249533, Winston-Salem, North Carolina, United States
- The Ohio State University /ID# 230439, Columbus, Ohio, United States
- Pennsylvania Oncology Hematolo /ID# 249637, Philadelphia, Pennsylvania, United States
- University of Wisconsin-Madiso /ID# 232612, Madison, Wisconsin, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
F. Hoffmann-La Roche Ltd; German CLL Study Group (GCLLSG); Dana-Farber Cancer Institute
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04895436 on ClinicalTrials.govOther trials for B-cell chronic lymphocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07194980Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaFred Hutchinson Cancer Center
- RECRUITINGEARLY PHASE1NCT07428707Immune Profiling of CLL/SLL Treated With First-Line PirtobrutinibNational Heart, Lung, and Blood Institute (NHLBI)
- RECRUITINGPHASE4NCT07218341A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaEli Lilly and Company
- RECRUITINGPHASE1NCT06859008Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCity of Hope Medical Center
- RECRUITINGPHASE2NCT07271667A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesCuris, Inc.
- RECRUITINGPHASE2NCT07014917Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLZulfa Omer
- RECRUITINGPHASE2NCT06958705Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor MonotherapyThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1, PHASE2NCT07052695Mosunetuzumab for CLL MRD ClearanceInhye Ahn